390 related articles for article (PubMed ID: 32655041)
1. Androgen deprivation therapy and side effects: are GnRH antagonists safer?
Freedland SJ; Abrahamsson PA
Asian J Androl; 2021; 23(1):3-10. PubMed ID: 32655041
[TBL] [Abstract][Full Text] [Related]
2. Update on cardiovascular and metabolic risk profiles of hormonal agents used in managing advanced prostate cancer.
Higano CS
Urol Oncol; 2020 Dec; 38(12):912-917. PubMed ID: 32900627
[TBL] [Abstract][Full Text] [Related]
3. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
4. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
[TBL] [Abstract][Full Text] [Related]
5. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
[TBL] [Abstract][Full Text] [Related]
6. Approach to Androgen Deprivation in the Prostate Cancer Patient with Pre-existing Cardiovascular Disease.
Greiman AK; Keane TE
Curr Urol Rep; 2017 Jun; 18(6):41. PubMed ID: 28417429
[TBL] [Abstract][Full Text] [Related]
7. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials.
Abufaraj M; Iwata T; Kimura S; Haddad A; Al-Ani H; Abusubaih L; Moschini M; Briganti A; Karakiewicz PI; Shariat SF
Eur Urol; 2021 Jan; 79(1):44-53. PubMed ID: 32605859
[TBL] [Abstract][Full Text] [Related]
8. Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.
Sasaki H; Miki K; Tashiro K; Mori K; Urabe F; Fukuokaya W; Kimura T; Sato S; Takahashi H; Aoki M; Egawa S
Andrology; 2022 Feb; 10(2):270-278. PubMed ID: 34510814
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular risk with androgen deprivation therapy.
Rosenberg MT
Int J Clin Pract; 2020 Mar; 74(3):e13449. PubMed ID: 31755635
[TBL] [Abstract][Full Text] [Related]
10. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
Kittai AS; Blank J; Graff JN
Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
[TBL] [Abstract][Full Text] [Related]
11. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
Clinton TN; Woldu SL; Raj GV
Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768
[TBL] [Abstract][Full Text] [Related]
12. Androgen Deprivation Therapies and Changes in Comorbidity: A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer.
Beckmann K; Garmo H; Adolfsson J; Bosco C; Johansson E; Robinson D; Holmberg L; Stattin P; Van Hemelrijck M
Eur Urol; 2019 Apr; 75(4):676-683. PubMed ID: 30497883
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular adverse events-related to GnRH agonists and GnRH antagonists: analysis of real-life data from Eudra-Vigilance and Food and Drug Administration databases entries.
Cicione A; Nacchia A; Guercio A; Gravina C; Franco A; Grimaldi MC; Tema G; Lombardo R; Tubaro A; De Nunzio C
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):765-771. PubMed ID: 36641533
[TBL] [Abstract][Full Text] [Related]
14. Does Exist a Differential Impact of Degarelix
Sciarra A; Busetto GM; Salciccia S; Del Giudice F; Maggi M; Crocetto F; Ferro M; De Berardinis E; Scarpa RM; Porpiglia F; Carmignani L; Damiano R; Artibani W; Carrieri G
Front Endocrinol (Lausanne); 2021; 12():695170. PubMed ID: 34194398
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data.
Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E
Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298
[TBL] [Abstract][Full Text] [Related]
16. [Cost effectiveness of GnRH antagonists in patients with prostate cancer and cardiovascular risk : Comparative analysis against Leuprorelin by the Number Needed to Treat].
Anderson D; Lehmann J; Ecker T; Vosgerau S; Donatz V
Urologe A; 2017 Jul; 56(7):917-924. PubMed ID: 28405705
[TBL] [Abstract][Full Text] [Related]
17. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
Merseburger AS; Sedding D; Hüter K
Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic and pharmacodynamic profile of degarelix for prostate cancer.
Klotz L
Expert Opin Drug Metab Toxicol; 2015; 11(11):1795-802. PubMed ID: 26513436
[TBL] [Abstract][Full Text] [Related]
19. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK.
Rosario DJ; Davey P; Green J; Greene D; Turner B; Payne H; Kirby M
World J Urol; 2016 Dec; 34(12):1601-1609. PubMed ID: 27097892
[TBL] [Abstract][Full Text] [Related]
20. [Cardiovascular side effects in patients undergoing androgen deprivation therapy: superiority of gonadotropin-releasing hormone antagonists? An update].
von Amsberg G; Thiele H; Merseburger A
Urologe A; 2021 Nov; 60(11):1450-1457. PubMed ID: 34213627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]